Effect of splenectomy on cellular immune function of patients with hepatitis C virus related cirrhotic portal hypertension

doi:10.3877/cma.j.issn.2095-3232.2015.04.010

Abstract

Abstract:

Objective

To investigate the effect of splenectomy on cellular immune function of patients with hepatitis C virus (HCV) related cirrhotic portal hypertension.

Methods

Twelve patients with HCV-related cirrhotic portal hypertension undergoing splenectomy + pericardial devascularization in the Second Affiliated Hospital of Xi'an Jiaotong University between December 2011 and December 2013 were enrolled in this prospective study. Among the 12 patients, 4 were males and 8 were females with the average age of (55±8) years old. Moreover, 12 healthy people were enrolled in the control group. The informed consents of all patients were obtained and the local ethical committee approval had been received. Percentage of natural killer (NK) cell, natural killer T (NKT) cell, CD4⁺ cell, CD8⁺ T cell and CD4⁺/CD8⁺ ratio in peripheral blood before and 2, 6 weeks after splenectomy were observed. The comparison on different lymphocyte subsets was conducted using Wilcoxon rank-sum test.

Results

The percentage of CD3^-CD56⁺CD16⁺ NK cell 6 weeks after splenectomy was 7.7%, which was significantly higher than 6.2% before splenectomy (T=1.992, P<0.05). And the percentage of CD56^dim NK cell 2 and 6 weeks after splenectomy was respectively 94.9% and 96.4%, which was significantly higher than 87.9% before splenectomy (T=2.747, 2.201; P<0.05). The percentage of CD56^bright NK cell 2 and 6 weeks after splenectomy was respectively 3.8% and 2.4%, which was significantly lower than 9.2% before splenectomy (T=2.747, 2.201; P<0.05). The percentage of CD3⁺CD56⁺ NKT cell 2 and 6 weeks after splenectomy was respectively 7.3% and 7.0%, which was significantly higher than 6.5% before splenectomy (T=2.275, 1.572; P<0.05). Percentage of CD4⁺ T cell 2 weeks after splenectomy was 41.7%, which was significantly lower than 45.7% before splenectomy (T=3.059, P<0.05), and further decreased to 26.7% 6 weeks after splenectomy (T=2.201, P<0.05), while percentage of CD8⁺ T cell increased from 21.1% before splenectomy to 24.8% 2 weeks after splenectomy (T=2.432, P<0.05), and further increased to 35.3% 6 weeks after splenectomy (T=1.992, P<0.05). The CD4⁺/CD8⁺ ratio before splenectomy was 2.0 and decreased to 1.4 and 0.8 respectively 2 and 6 weeks after splenectomy (T=2.981, 1.992; P<0.05).

Conclusion

The cellular immune function of patients with HCV related cirrhotic portal hypertension after splenectomy improves significantly.

Key words: Liver cirrhotic, Hepatitis C, chronic, Splenectomy, NK cell, T lymphocytes

Fanpu Ji, Na Huang, Shu Zhang, Zhifang Cai, An Jiang, Rui Zhou, Baohua Li, Song Ren, Zongfang Li. Effect of splenectomy on cellular immune function of patients with hepatitis C virus related cirrhotic portal hypertension[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015, 04(04): 232-236.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2015.04.010

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2015/V04/I04/232

Figures/Tables 2

References 18

[1]	Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(9): 553-562.
[2]	Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[J]. J Hepatol, 2014,61 Suppl 1: S45-57.
[3]	张澍，李宗芳．脾脏功能与脾脏外科研究现状与展望[J]．中华实验外科杂志，2014, 31(2): 231-233.
[4]	Rosen HR. Emerging concepts in immunity to hepatitis C virus infection[J]. J Clin Invest, 2013, 123(10): 4121-4130.
[5]	Sugimoto K, Shiraki K. Different aspects of CD4 T cells that lead to viral clearance or persistence of HCV infection [J]. Hepatol Int, 2012, 6(1): 350-355.
[6]	Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? the example of natural killer cells[J]. Science, 2011, 331(6013): 44-49.
[7]	Jost S, Altfeld M. Control of human viral infections by natural killer cells[J]. Annu Rev Immunol, 2013(31): 163-194.
[8]	Lunemann S, Schlaphoff V, Cornberg M, et al. NK cells in hepatitis C: role in disease susceptibility and therapy[J]. Dig Dis, 2012, 30 Suppl 1: 48-54.
[9]	De Maria A, Bozzano F, Cantoni C, et al. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16⁺ NK cells as rapid producers of abundant IFN-gamma on activation[J]. Proc Natl Acad Sci U S A, 2011, 108(2): 728-732.
[10]	Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, et al. Broadly directed virus-specific CD4⁺ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence[J]. J Exp Med, 2012, 209(1): 61-75.
[11]	Hashimoto N, Shimoda S, Kawanaka H, et al. Modulation of CD4⁺ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis[J]. Clin Exp Immunol, 2011, 165(2): 243-250.
[12]	Nomura Y, Kage M, Ogata T, et al. Influence of splenectomy in patients with liver cirrhosis and hypersplenism[J]. Hepatol Res, 2014, 44(10): E100-109.
[13]	谢玉梅，李冰，马力，等．丙型肝炎肝硬化患者脾切除或脾栓塞术后抗病毒治疗的疗效观察[J]．中华肝脏病杂志, 2012, 20(2): 112-115.
[14]	Ji F, Zhang S, Huang N, et al. Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis [J]. Braz J Infect Dis, 2013, 17(5): 601-605.
[15]	Bozzano F, Picciotto A, Costa P, et al. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment[J]. Eur J Immunol, 2011, 41(10): 2905-2914.
[16]	Oliviero B, Mele D, Degasperi E, et al. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection[J]. J Hepatol, 2013, 59(1): 38-44.
[17]	Xiao YS, Gao Q, Xu XN, et al. Combination of intratumoral invariant natural killer T cells and interferon-gamma is associated with prognosis of hepatocellular carcinoma after curative resection[J]. PLoS One, 2013, 8(8): e70345.
[18]	Werner JM, Heller T, Gordon AM, et al. Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection[J]. Hepatology, 2013, 58(5): 1621-1631.

组别		例数	CD3^-CD56⁺CD16⁺ NK	CD56^dim NK	CD56^bright NK	CD3⁺CD56⁺ NKT
对照组		12	18.2(6.1～42.2)	95.8(84.6～98.6)	4.2(1.4～15.4)	4.2(1.1～13.8)
研究组		?	?	?	?	?
?	术前	12	6.2(2.6～18.7) ^a	87.9(74.4～98.7)^a	9.2(1.3～25.6)^a	6.5(3.2～12.8)
?	术后2周	12	6.9(3.1～24.5)	94.9(83.0～98.8)^b	3.8(1.2～17.0)^b	7.3(3.1～14.3)^b
?	术后6周	12	7.7(5.0～24.2)^b	96.4(90.6～98.3)^b	2.4(1.7～9.4)^b	7.0(5.4～16.4)

组别		例数	CD3^-CD56⁺CD16⁺ NK	CD56^dim NK	CD56^bright NK	CD3⁺CD56⁺ NKT
对照组		12	18.2(6.1～42.2)	95.8(84.6～98.6)	4.2(1.4～15.4)	4.2(1.1～13.8)
研究组		?	?	?	?	?
?	术前	12	6.2(2.6～18.7) ^a	87.9(74.4～98.7)^a	9.2(1.3～25.6)^a	6.5(3.2～12.8)
?	术后2周	12	6.9(3.1～24.5)	94.9(83.0～98.8)^b	3.8(1.2～17.0)^b	7.3(3.1～14.3)^b
?	术后6周	12	7.7(5.0～24.2)^b	96.4(90.6～98.3)^b	2.4(1.7～9.4)^b	7.0(5.4～16.4)

组别		例数	CD4⁺ T（%）	CD8⁺ T（%）	CD4⁺/CD8⁺比值
对照组		12	36.1(28.3～59.7)	30.4(13.9～41.1)	1.2(0.9～2.2)
研究组		?	?	?	?
?	术前	12	45.7(38.4～63.7) ^a	21.1(16.6～35.6)^a	2.0(1.1～3.4)^a
?	术后2周	12	41.7(28.0～55.6) ^b	24.8(18.4～39.2)^b	1.4(0.8～3.0) ^b
?	术后6周	12	26.7(24.2～51.4) ^b	35.3(15.1～44.8) ^b	0.8(0.6～3.4) ^b

组别		例数	CD4⁺ T（%）	CD8⁺ T（%）	CD4⁺/CD8⁺比值
对照组		12	36.1(28.3～59.7)	30.4(13.9～41.1)	1.2(0.9～2.2)
研究组		?	?	?	?
?	术前	12	45.7(38.4～63.7) ^a	21.1(16.6～35.6)^a	2.0(1.1～3.4)^a
?	术后2周	12	41.7(28.0～55.6) ^b	24.8(18.4～39.2)^b	1.4(0.8～3.0) ^b
?	术后6周	12	26.7(24.2～51.4) ^b	35.3(15.1～44.8) ^b	0.8(0.6～3.4) ^b

Please choose a citation manager

Content to export